Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Validity of composite end points in clinical trials.

Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH.

BMJ. 2005 Mar 12;330(7491):594-6. Review. No abstract available.

2.

Measurement of end points in heart failure trials: jousting at windmills?

Hauptman PJ.

Mt Sinai J Med. 2004 Oct;71(5):298-304. Review.

PMID:
15543430
3.

The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.

Kip KE, Hollabaugh K, Marroquin OC, Williams DO.

J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034. Review.

4.

End points and clinical trial design in pulmonary arterial hypertension.

McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. doi: 10.1016/j.jacc.2009.04.007. Review.

5.

Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.

Le Tourneau C, Michiels S, Gan HK, Siu LL.

J Clin Oncol. 2009 Dec 10;27(35):5965-71. doi: 10.1200/JCO.2009.22.3685. Epub 2009 Oct 5. Review.

PMID:
19805677
6.

[Surrogate end point fallacies -- the urge for randomized trials with clinical endpoints].

Mühlhauser I, Meyer G.

Psychother Psychosom Med Psychol. 2006 May;56(5):193-201. Epub 2006 Mar 3. Review. German.

PMID:
16586306
7.

Forty years of antidepressant drug trials.

Barbui C, Hotopf M.

Acta Psychiatr Scand. 2001 Aug;104(2):92-5. Review.

PMID:
11473501
8.

Some issues with composite endpoints in clinical trials.

Chi GY.

Fundam Clin Pharmacol. 2005 Dec;19(6):609-19. Review.

PMID:
16313272
9.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.

Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F; American Heart Association.

Circulation. 2004 Jun 1;109(21):e302-4. Review. No abstract available.

10.

The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.

Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F; American Heart Association.

Circulation. 2004 Jun 1;109(21):e305-7. Review. No abstract available.

11.

Assessing the validity of clinical trials.

Akobeng AK.

J Pediatr Gastroenterol Nutr. 2008 Sep;47(3):277-82. doi: 10.1097/MPG.0b013e31816c749f. Review.

PMID:
18728521
12.

Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.

Kohro T, Yamazaki T.

Hypertens Res. 2009 Feb;32(2):109-14. doi: 10.1038/hr.2008.26. Epub 2009 Jan 16. Review.

PMID:
19262468
13.

End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.

Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A.

J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):48S-55S. Review.

14.
15.

Randomized, controlled clinical trials in sepsis: has methodological quality improved over time?

Graf J, Doig GS, Cook DJ, Vincent JL, Sibbald WJ.

Crit Care Med. 2002 Feb;30(2):461-72. Review.

PMID:
11889331
16.

Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration.

Joussen AM, Lehmacher W, Hilgers RD, Kirchhof B.

Surv Ophthalmol. 2007 May-Jun;52(3):266-78. Review.

PMID:
17472802
17.

Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity.

Colagiuri B.

Clin Trials. 2010 Jun;7(3):246-55. doi: 10.1177/1740774510367916. Epub 2010 Apr 26. Review.

PMID:
20421243
18.

Design of randomized controlled trials.

Stanley K.

Circulation. 2007 Mar 6;115(9):1164-9. Review. No abstract available.

19.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Suman VJ, Dueck A, Sargent DJ.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Review. No abstract available.

PMID:
18568764
20.

Novel procedures for validating surrogate endpoints in clinical trials.

Cleophas TJ, Zwinderman AH, Chaib AH.

Curr Clin Pharmacol. 2007 May;2(2):123-8. Review.

PMID:
18690859

Supplemental Content

Support Center